Key result
Potassium-targeted therapy cuts the risk of suboptimal biventricular pacing ~52% vs. standard care.
Why the study?
Low-normal potassium levels promote atrial and ventricular ectopy and may impair biventricular pacing delivery in CRT patients. Whether increasing plasma potassium toward high-normal levels prevents episodes of suboptimal biventricular pacing <90% was unknown.
Does potassium-targeted therapy aiming for plasma potassium levels between 4.5 and 5.0 mmol/L prevent episodes of suboptimal biventricular pacing (<90%) in patients with a CRT-defibrillator?
RCT (n=230)
1:1 ratio
Does potassium-targeted therapy aiming for plasma potassium levels between 4.5 and 5.0 mmol/L prevent episodes of suboptimal biventricular pacing (<90%) in patients with a CRT-defibrillator?
In patients with a CRT-defibrillator, targeting high-normal plasma potassium levels (4.5-5.0 mmol/L) via dietary guidance, MRAs, and/or potassium supplements significantly reduces the risk of losing optimal biventricular pacing (<90%).
Supports potassium-targeted therapy to sustain biventricular pacing in CRT-D patients; extends electrolyte optimization evidence to device performance.
Background Optimal cardiac resynchronization therapy (CRT) requires near-continuous biventricular pacing. Loss of biventricular pacing is associated with an increased risk of heart-failure hospitalization and death. Low-normal potassium levels promote atrial and ventricular ectopy and may impair pacing delivery. Purpose To assess whether an intervention aimed at increasing plasma potassium levels toward high-normal levels prevents episodes of suboptimal biventricular pacing <90%. Methods In this prespecified analysis of the randomised POTCAST trial, participants with a CRT-defibrillator (CRT-D) were included. POTCAST randomised participants in a 1:1 ratio to potassium-targeted therapy in addition to standard care or standard care alone. The intervention included dietary guidance and a) mineralocorticoid receptor antagonists (MRAs), b) potassium supplements, or c) a combination of both, targeting a plasma potassium level between 4.5 and 5.0 mmol/L. The primary outcome was time to first drop in biventricular pacing <90%, analysed using Cox proportional hazards regression. The secondary outcome was the association between measured plasma potassium levels and risk of biventricular pacing <90%, analysed using generalized additive logistic models applied to paired plasma potassium and biventricular pacing measurements obtained at biannual follow-up visits. Results Among 230 participants (mean age 65 ± 10 years, 22% female) treated with CRT in the POTCAST trial, 119 were assigned to the intervention group and 111 to the control group. Baseline characteristics, including plasma potassium levels, were well balanced between groups (Table 1). At biannual visits, mean plasma potassium levels in the intervention group were 0.20-0.27 mmol/L higher than in controls (all p<0.015). The risk of suboptimal biventricular pacing was significantly reduced in the intervention group compared with controls (HR 0.48, 95% CI 0.25-0.92; p=0.026) (Figure 1). Across plasma potassium levels between 3.4 and 5.0 mmol/L, higher potassium levels were associated with a lower probability of biventricular pacing <90% (p=0.0004). Conclusions In patients with CRT, increasing plasma potassium levels toward high-normal concentrations prevented loss of biventricular pacing.
No takes yet. Share an insight, caveat, or question.
Danielsen et al. (2026) conducted an RCT in Cardiac resynchronization therapy-defibrillator (CRT-D) recipients (n=230). Potassium-targeted therapy (dietary guidance, MRAs, and/or potassium supplements) plus standard care vs. Standard care alone was evaluated on Time to first drop in biventricular pacing <90% (HR 0.48, 95% CI 0.25-0.92, p=0.026). Potassium-targeted therapy (target 4.5-5.0 mmol/L) significantly reduced the risk of suboptimal biventricular pacing (<90%) compared with standard care alone (HR 0.48, 95% CI 0.25-0.92; p=0.026).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: